Journal of Cancer Policy最新文献

{"title":"Central and Eastern Europe: A crucible for clinical cancer innovation?","authors":"Mark Lawler ,&nbsp;Susan Bhatti ,&nbsp;Pawel Przewiezlikowski ,&nbsp;Birgit Wolf ,&nbsp;Joanna Frątczak-Kazana ,&nbsp;Piotr Rutkowski ,&nbsp;Peter Šišovský ,&nbsp;Lidia Zielińska ,&nbsp;Axel Glasmacher","doi":"10.1016/j.jcpo.2025.100647","DOIUrl":"10.1016/j.jcpo.2025.100647","url":null,"abstract":"<div><div>Clinical research in oncology is essential for improving patient outcomes; however, cancer care provision and access to novel therapies remains highly heterogeneous across Europe, particularly between Western and Eastern EU27 regions. This has been further compounded by the Russian invasion of Ukraine, severely disrupting regional cancer treatment, research infrastructures and clinical trials activity. Challenges to clinical research in the Central and Eastern regions of the European Union (EU27-CEE) are multifactorial, relating to patient access, local implementation and conduct of trials, education, infrastructure and regulatory procedures. Nevertheless, EU27-CEE comprises a very active clinical trial landscape with its specialist workforce, high productivity and quality of data, empowering a growing regional pharmaceutical industry and establishing itself as an important clinical cancer research hub for conducting global trials. Consequently, patients recruited in EU27-CEE exercise an important impact on global cancer drug development. Poland has proven to be a model for biomedical innovation, serving as the region’s blueprint for a productive clinical trials ecosystem. Multi-stakeholder collaboration and patient-centric approaches are required to streamline procedures for quicker trial initiation, simpler trial conduct, and better cross-border access. Recognizing these challenges and opportunities, we have developed, through a consultative approach, a Call to Action that, if implemented, would enhance the cancer clinical trials landscape in EU27-CEE countries and empower patient access to the latest advances and therapies in cancer drug development.</div></div>","PeriodicalId":38212,"journal":{"name":"Journal of Cancer Policy","volume":"46 ","pages":"Article 100647"},"PeriodicalIF":2.0,"publicationDate":"2025-10-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145313902","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Indirect economic burden of cancer in populations in China, 2021: A measurement based on a human capital approach","authors":"Xin-Yi Zhou ,&nbsp;Xin Wang ,&nbsp;Sen-Yao Cai ,&nbsp;Yan-Jie Li ,&nbsp;Jie-Bin Lew ,&nbsp;Wanqing Chen ,&nbsp;Ju-Fang Shi","doi":"10.1016/j.jcpo.2025.100648","DOIUrl":"10.1016/j.jcpo.2025.100648","url":null,"abstract":"<div><h3>Objectives</h3><div>Cancer imposes an enormous burden. In China, research on cancer economic burden has primarily focused on the direct economic burden while the indirect economic burden of cancer (IEBC) has been overlooked. Therefore, we aimed to conduct a systematic quantification of IEBC in populations in China.</div></div><div><h3>Methods</h3><div>A human capital approach was used to estimate the IEBC. The loss of productivity time was approximated based on disability-adjusted life years (DALYs) from the GBD 2021. The labour force participation rate and per capita economic parameters were sourced from various datasets, and subgroup and sensitivity analyses were conducted. The indirect-to-direct economic burden ratio was estimated partially based on results from a literature review.</div></div><div><h3>Results</h3><div>The overall IEBC in populations in China was estimated to be CNY1014.4 billion in 2021, representing 0.89 % of the gross domestic product (GDP). Among this total, CNY990.3 billion (97.6 %) was attributed to premature death and CNY24.1 billion to disability; CNY822.3 billion (81.1 %) to males and CNY853.8 billion (84.2 %) to populations under the age of 60 years. Region heterogeneity was observed to be CNY26.5 billion for the Northwest and CNY263.7 billion for the East. Of the overall IEBC, 58.8 % (CNY596.9 billion) could be attributed to a range of modifiable risk factors (tobacco was the leading one at CNY304.6 billion); 76.0 % (CNY770.8 billion) was attributed to screening-targeted cancers, mainly gastrointestinal cancers (CNY458.2 billion), lung cancer (CNY232.9 billion), breast and cervical cancer (CNY57.2 billion). The by-cancer median value of the indirect-to-direct economic burden ratio was 2.56 (range 0.83–4.76).</div></div><div><h3>Conclusions</h3><div>The previously underestimated IEBC was roughly 3 times the reported direct economic burden in populations in China. Systematic quantification of the IEBC from \"preventable\" and \"screenable\" cancer types suggests there to be a potential extent of future economic benefit of implementing more effective and scaled-up population-based primary and secondary interventions.</div></div>","PeriodicalId":38212,"journal":{"name":"Journal of Cancer Policy","volume":"46 ","pages":"Article 100648"},"PeriodicalIF":2.0,"publicationDate":"2025-10-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145313954","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Invisible geographies - the rural and coastal blind spot in UK cancer policy: A content analysis","authors":"David Nelson ,&nbsp;Natalia Calanzani ,&nbsp;Ben Pickwell-Smith ,&nbsp;Katie Spencer ,&nbsp;Samuel Cooke ,&nbsp;Tanja K. Kleinhappel ,&nbsp;Maxime Inghels ,&nbsp;Kathie McPeake ,&nbsp;Ros Kane ,&nbsp;Shahana A. Naqvi ,&nbsp;Eila Watson ,&nbsp;Anna Prytherch ,&nbsp;Rebecca Foster ,&nbsp;Lynn Calman ,&nbsp;Peter Selby ,&nbsp;Mark Lawler ,&nbsp;Peter Murchie","doi":"10.1016/j.jcpo.2025.100650","DOIUrl":"10.1016/j.jcpo.2025.100650","url":null,"abstract":"<div><h3>Background</h3><div>The United Kingdom’s (UK) diverse geography means many people live in rural and coastal areas, where cancer outcomes are often poorer than in urban settings. Devolution means that the four nations of the UK have distinct approaches to cancer care. Scotland, Wales, and Northern Ireland have recently published national cancer strategies, while England’s new plan is expected later in 2025. This study examined UK cancer policy documents, to identify, how, and to what extent, rural or coastal issues were considered.</div></div><div><h3>Methods</h3><div>UK cancer policy documents from 2000 to 2024 were sourced via The International Cancer Control Partnership (ICCP) website (<span><span>https://iccp-portal.org/</span><svg><path></path></svg></span>), UK government sites and Google. Documents were searched for rural and coastal related terms.</div></div><div><h3>Results</h3><div>Fifty-five documents were included (England n = 17; Northern Ireland n = 10; Scotland n = 21; Wales n = 7). No recent policies included a specific section or explicit recommendations for rural or coastal cancer care. Across the policies, contextual analysis highlighted that terms to promote rural or coastal equity rarely appeared within recommendations. Northern Ireland gave more attention to rural issues than other nations, as evidenced by a rural needs impact assessment and supporting documents to inform Northern Ireland’s Cancer Strategy 2022–2032.</div></div><div><h3>Conclusion</h3><div>Despite sizeable rural and coastal populations facing specific health challenges across the UK, national cancer policies excepting Northern Ireland gave minimal guidance for delivering cancer care tailored to these communities. Other UK nations should consider adopting more rural-centric approaches like Northern Ireland.</div></div><div><h3>Policy summary</h3><div>Coastal and rural health issues have received policy attention via the Chief Medical Officer for England’s annual reports (2021; 2023) and more recently in the UK Government’s 10 Year Health Plan for England (July 2025). However, when it comes to high-level cancer policy across the UK, the needs of rural and coastal people with cancer are not being adequately or specifically recognised.</div></div>","PeriodicalId":38212,"journal":{"name":"Journal of Cancer Policy","volume":"46 ","pages":"Article 100650"},"PeriodicalIF":2.0,"publicationDate":"2025-10-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145309629","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Longitudinal validation of the PROFFIT questionnaire to assess financial toxicity in cancer patients","authors":"L. Arenare ,&nbsp;C. Porta ,&nbsp;D. Barberio ,&nbsp;S. Terzolo ,&nbsp;V. Zagonel ,&nbsp;S. Pisconti ,&nbsp;L. Del Mastro ,&nbsp;C. Pinto ,&nbsp;D. Bilancia ,&nbsp;S. Cinieri ,&nbsp;M. Rizzo ,&nbsp;G. Migliaccio ,&nbsp;V. Montesarchio ,&nbsp;L. Del Campo ,&nbsp;F. De Lorenzo ,&nbsp;E. Iannellil ,&nbsp;L. Gitto ,&nbsp;C.M. Vaccaro ,&nbsp;L. Frontini ,&nbsp;D. Giannarelli ,&nbsp;F. Perrone","doi":"10.1016/j.jcpo.2025.100645","DOIUrl":"10.1016/j.jcpo.2025.100645","url":null,"abstract":"<div><h3>Background</h3><div>Financial toxicity (FT) is a growing issue for cancer patients worldwide. The PROFFIT questionnaire was developed in Italy to measure FT and identify its determinants in cancer patients within a public health system.</div></div><div><h3>Methods</h3><div>A prospective study was conducted with 221 cancer patients from 10 Italian centres between March 2021 and July 2022 to validate the PROFFIT questionnaire in patients undergoing active treatment. The PROFFIT and EORTC-QLQ-C30 questionnaires were administered. Statistical analyses were performed on the PROFFIT-score (items 1–7), the financial difficulties item (Q28), and the global health status/quality of life (HR-QOL) scale from the EORTC-QLQ-C30. Geographic disparities were also analysed.</div></div><div><h3>Results</h3><div>A total of 1149 questionnaires were completed (83 % paper-based, 17 % electronically). The median observation period was 5 months (IQR 4.5–5.8). Missing phenomenon increased over time but was not affected by the baseline PROFFIT-score. PROFFIT-score remained stable throughout treatment, with patients in Southern Italy reporting higher (worse) values. Significant associations (p &lt; 0.0001) were found between PROFFIT-score and Q28 at all time-points. Moderate inverse correlations were observed between PROFFIT-score and HR-QOL.</div></div><div><h3>Conclusions</h3><div>PROFFIT shows strong longitudinal validity for assessing FT in cancer patients. PROFFIT-score does not significantly change during treatment, but regional disparities highlight the need for targeted interventions, particularly in underserved areas. Further research will define cut-off values and explore FT dynamics across different patient populations.</div></div><div><h3>Policy Summary</h3><div>PROFFIT validation analyses make the instrument suitable to measure FT in cancer patients within public health systems. In addition, it may represent a valuable tool to plan specific local health policies being sensible to macro-regional variability. Finally, on the long run, it might be useful to test the impact of policies implemented against FT.</div></div>","PeriodicalId":38212,"journal":{"name":"Journal of Cancer Policy","volume":"46 ","pages":"Article 100645"},"PeriodicalIF":2.0,"publicationDate":"2025-10-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145240040","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Seizing the opportunity to leverage home-based palliative care for cancer education and screening in high-burden and resource-limited settings in India","authors":"Laxman Kumar Mahaseth ,&nbsp;Subhadra Goala ,&nbsp;Vidhubala Elangovan ,&nbsp;Kathirvel Soundappan ,&nbsp;Krishnakumar Rathnam ,&nbsp;Bibha Thapa ,&nbsp;Kanan Singha ,&nbsp;Ravi Kannan","doi":"10.1016/j.jcpo.2025.100646","DOIUrl":"10.1016/j.jcpo.2025.100646","url":null,"abstract":"<div><h3>Background</h3><div>Despite national screening efforts and a high cancer burden, the cancer screening rate is low in the northeast region of India. Seizing every opportunity for early detection is crucial in reducing cancer-related morbidity and mortality. This study assessed the outcomes of cancer education and symptom screening (CESS) among family members and neighbours of cancer patients on home-based palliative care (Home-PC) in Barak Valley of Assam, India.</div></div><div><h3>Methods</h3><div>This is a retrospective cohort study based on record review. Trained lay health workers (TLHW) attached to a tertiary cancer hospital conducted CESS sessions (self-administered or facilitated questionnaire) during routine Home-PC visits.</div></div><div><h3>Results</h3><div>Of 916 individuals, 75 (8.2 %) reported cancer-related symptoms and 33 (44 %) attended the screening OPD of a tertiary hospital for assessment. Of them, 17 (51.5 %) were diagnosed with cancer, predominantly oral, breast, and other cancers. The median (interquartile range) days from symptom screening to screening OPD visit was 10 (2.5, 49.5) days, while from screening OPD visit to diagnosis was 1 (0, 8) day.</div></div><div><h3>Conclusion</h3><div>Integrating CESS into Home-PC is feasible and aids in prompt diagnosis in resource-limited settings. This strategy could be used as an opportunity for early cancer detection and management, especially in high-burden regions like Northeast India.</div></div>","PeriodicalId":38212,"journal":{"name":"Journal of Cancer Policy","volume":"46 ","pages":"Article 100646"},"PeriodicalIF":2.0,"publicationDate":"2025-10-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145233462","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Time to rethink diffusion modality of preliminary results from industry-sponsored clinical trials in oncology: Considerations from the Italian Network of Cancer Patients (ROPI).","authors":"Stefania Gori","doi":"10.1016/j.jcpo.2025.100644","DOIUrl":"10.1016/j.jcpo.2025.100644","url":null,"abstract":"","PeriodicalId":38212,"journal":{"name":"Journal of Cancer Policy","volume":"46 ","pages":"Article 100644"},"PeriodicalIF":2.0,"publicationDate":"2025-09-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145182312","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Promoting a research agenda for cancer treatment for intravenous devices with clinicians in Europe; the PRACTICE survey","authors":"Caitriona Duggan ,&nbsp;Orlaith Hernon ,&nbsp;Andrew J. Simpkin ,&nbsp;Viktor Manasek ,&nbsp;Julio C. de la Torre-Montero ,&nbsp;Paulo Santos-Costa ,&nbsp;Jonathan G. Moss ,&nbsp;Christina H. Ruhlmann ,&nbsp;Knut Taxbro ,&nbsp;Miguel Angel Rodriguez- Calero ,&nbsp;Rodrigo Oom ,&nbsp;Rita Barroca ,&nbsp;Onagh O. Grady ,&nbsp;Jacqueline Daly ,&nbsp;Ian Blanco-Mavillard ,&nbsp;Nikolina Dodlek ,&nbsp;Jiri Charvát ,&nbsp;Saloa Unanue-Arza ,&nbsp;Bibiana Krakovska ,&nbsp;Peter J. Carr","doi":"10.1016/j.jcpo.2025.100643","DOIUrl":"10.1016/j.jcpo.2025.100643","url":null,"abstract":"<div><h3>Aims</h3><div>The <em>PRACTICE</em> survey aimed to characterize vascular access device (VAD) practices for systemic anti-cancer therapy (SACT) across Europe, addressing gaps in clinician decision-making, training, and complication management.</div></div><div><h3>Methods</h3><div>Conducted as a cross-sectional survey from May to October 2024, the study engaged healthcare professionals (HCPs) from 18 European countries, with 403 completing demographic questions and 166 responding to procedural and training-related queries.</div></div><div><h3>Results</h3><div>Results revealed significant variability in VAD selection, influenced by institutional protocols, geographic location, and the presence of vascular access teams (VATs). Oncologists were identified as primary decision-makers (36 %), though nursing staff played a pivotal role in daily management. Peripheral intravenous catheters (PIVCs) dominated in Ireland and Finland (43–49 %), while tunnelled implantable devices (TIVADs) were preferred in Belgium (65 %). Barriers to optimal VAD selection included insufficient training (80 % sought further education) and inconsistent guideline adoption (51 % reported institutional protocols).</div></div><div><h3>Conclusion</h3><div>The study underscores the need for standardised practices, interdisciplinary collaboration, and enhanced training. Findings highlight opportunities for integrating VAD selection into cancer care certification metrics and fostering partnerships between oncology and vascular access societies.</div></div>","PeriodicalId":38212,"journal":{"name":"Journal of Cancer Policy","volume":"46 ","pages":"Article 100643"},"PeriodicalIF":2.0,"publicationDate":"2025-09-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145139085","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Exploring experiences of reasonable adjustments in cancer care among patients with disabilities and their carers: A focus group study in South West England","authors":"Selin Siviş ,&nbsp;Andrew Turner ,&nbsp;Hannah Little ,&nbsp;Shamim Kholwadia ,&nbsp;Ruth Hendy ,&nbsp;Fiona Spence ,&nbsp;Gifty Markey ,&nbsp;Jon Banks","doi":"10.1016/j.jcpo.2025.100641","DOIUrl":"10.1016/j.jcpo.2025.100641","url":null,"abstract":"<div><h3>Background</h3><div>The UK Equality Act 2010 mandates equal access to healthcare for people with disabilities. For those with disabilities who have also been diagnosed with cancer, addressing these needs is complex and multifaceted. Whilst existing research has primarily focused on reasonable adjustments for individuals with learning disabilities or autism, this study broadens the scope to include physical disabilities, cognitive or sensory impairments, and mental health conditions.</div></div><div><h3>Aim</h3><div>This study aimed qualitatively explore and understand the experiences of individuals with disabilities requiring reasonable adjustments, who have direct or indirect exposure to cancer treatment within the cancer care setting, as well as the experiences of their carers.</div></div><div><h3>Methods</h3><div>Qualitative study based on seven focus groups with 44 participants who have direct or indirect experience of cancer treatment and experience of one or more of a range of conditions that may require reasonable adjustments. Thematic analysis was used inductively to explore patterns.</div></div><div><h3>Results</h3><div>Participants described various care pathway adjustments but also noted their limited effectiveness. The main concern was a lack of alignment with individual needs. Three key areas for improvement emerged: (1) communication and coordination (e.g., clearer signposting, longer appointments, better understanding of needs); (2) support for family and carers (e.g., tailored adjustments for caregivers, clearer explanations); and (3) adherence to compassion and empathy (e.g., avoiding jargon, using accessible language, and ensuring patients feel heard).</div></div><div><h3>Conclusion</h3><div>Reasonable adjustments are necessary but not sufficient for equitable care. Participants emphasised the need for an integrated approach to individual needs to ensure adjustments are both accessible and effective.</div></div><div><h3>Policy summary</h3><div>An integrated understanding of individuals’ and their family carers’ needs should underpin approaches to reasonable adjustments by healthcare providers. A first step to achieving this is to develop training for healthcare professionals to encompass a broader understanding of reasonable adjustments beyond legal categories.</div></div>","PeriodicalId":38212,"journal":{"name":"Journal of Cancer Policy","volume":"46 ","pages":"Article 100641"},"PeriodicalIF":2.0,"publicationDate":"2025-09-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145103086","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A comparison of the cost-effectiveness of HPV (self-sampling and health care provider sampling) versus VIA for cervical cancer screening in India","authors":"Apourv Pant,&nbsp;Gowthaman Thangavel,&nbsp;Stany Mathew,&nbsp;Anita Nath","doi":"10.1016/j.jcpo.2025.100642","DOIUrl":"10.1016/j.jcpo.2025.100642","url":null,"abstract":"<div><div>Cervical cancer ranks as the fourth most common cancer in women globally and the second most prevalent in India. Preventive measures, such as HPV vaccination and various screening methods, are essential. Despite these strategies, the economic burden of cervical cancer remains significant due to its long-term nature and treatment costs. This study evaluates the cost-effectiveness of three screening approaches—VIA, HPV physician sampling, and HPV self-sampling—for women aged 30–65. A Markov-based cost-utility analysis with a lifetime horizon and one-year cycle length was conducted. Model parameters were sourced from peer-reviewed literature, national cancer registries, and health economic studies. Deterministic and probabilistic sensitivity analyses were performed to ensure the robustness of the results. Health Provider HPV sampling yielded the highest Quality-Adjusted Life Years (QALYs) at 5.97 (three years) and 4.28 (five years), compared to VIA’s 4.01 (three years) and 2.9 (five years), and HPV self-sampling’s 4.71 (three years) and 3.41 (five years). Over 30 cycles for 100,000 women, healthcare provider sampling achieved a maximum QALY gain of 13.40. Compared to other methods, it offered a gain of 2.94 QALYs at an incremental cost of 19,409 INR. While VIA screening is cost-saving, it provides reduced health benefits. HPV healthcare provider sampling is more cost-effective in terms of QALYs gained despite higher screening costs. A policy analysis is necessary to achieve 70 % cervical cancer screening coverage in India, focusing on current HPV screening strategies and identifying areas for improvement.</div></div>","PeriodicalId":38212,"journal":{"name":"Journal of Cancer Policy","volume":"46 ","pages":"Article 100642"},"PeriodicalIF":2.0,"publicationDate":"2025-09-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145103065","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Psycho-oncology in India","authors":"J. Deodhar ,&nbsp;P. Nayak ,&nbsp;C.S. Pramesh ,&nbsp;A. Purushotham","doi":"10.1016/j.jcpo.2025.100640","DOIUrl":"10.1016/j.jcpo.2025.100640","url":null,"abstract":"<div><div>Psychosocial care is essential for high-quality cancer care. Psycho-oncology is a developing discipline globally. A narrative review was conducted of studies published in India from 2000 to 2024 on psychosocial care in patients with cancer. Of 233 papers identified, 85 were included. Distress rates ranged from 22 % to 62 % with the highest being in head and neck and breast cancer. Seven tools for measuring distress have been validated in a few Indian languages. Cancer-related communication revealed high rates of collusion and use of euphemisms. There is a paucity of intervention studies. Few studies described psychosocial issues in children and adolescents and older adults.Therefore, future high-quality intervention and outcome studies are required. There is an urgent need for the inclusion of psycho-oncology in national cancer control policy globally.</div></div>","PeriodicalId":38212,"journal":{"name":"Journal of Cancer Policy","volume":"46 ","pages":"Article 100640"},"PeriodicalIF":2.0,"publicationDate":"2025-09-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145087645","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}